Skip to main content
. 2018 May 10;2018(5):CD012069. doi: 10.1002/14651858.CD012069.pub2

Kim 2015a.

Methods A cohort study of methylphenidate use for 12 weeks
Participants Number of participants screened: not stated
Number of participants included: 86
Number of participants followed up: 37
Number of withdrawals: 49
Diagnosis of ADHD: DSM‐IV (subtype: inattentive, hyperactive‐impulsive or both)
Age: mean 8
IQ: > 70
Sex: 34 males, 3 females
Methylphenidate‐naïve: 2‐month washout period prior to study
Ethnicity: not stated
Country: Korea
Comorbidity: none
Comedication: none
Sociodemographics: none
Inclusion criteria
  1. Patients diagnosed at the Korea University Medical Centre between August 2007‐December 2010 attending outpatient clinic

  2. Showing signs and symptoms of either inattention or hyperactivity‐impulsivity or both according to DSM‐IV‐TR criteria for ADHD


Exclusion criteria
  1. Medical problems requiring special attention such as cardiovascular disorders, learning disabilities and mental retardation

  2. Other psychiatric comorbidities

Interventions Methylphenidate type: immediate release or extended release
Mean methylphenidate dosage: 22.23 (SD 8.93) mg/0.70 (SD 0.20) mg/kg
Administration schedule: not stated
Duration of intervention: 12 weeks
Treatment compliance: 43% completed 12 week programme
Outcomes Non‐serious adverse events:
All participants were evaluated for adverse events during each visit, and an interview with their care providers was conducted
Notes Sample calculation: no
Ethics approval: study approved by Institutional Review Board of Guro Hospital, Korea University Medical Center
Funding/vested interests: financial support from Jun Sang‐Bae Child and Adolescent Psychiatry Research Grant from the Korean Foundation of Neuropsychiatric Research
Key conclusions of the study authors: HF and RMSSD suggested that parasympathetic dominance in ADHD can be changed by methylphenidate treatment
Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: not stated
Supplemental information requested twice from the study authors in May and June 2016 with no reply